News 
Market Data 
Discover
Replies to post #689047 on NorthWest Biotherapeutics Inc (NWBO)
05/05/24 9:32 AM
This article is in Daily Mail regarding cancer vaccines
https://www.dailymail.co.uk/health/article-13373447/amp/Cancer-vaccine-treatment-brain-tumour-glioblastoma-Tom-Parker.html
Article in full text:
"There are hopes that a pioneering new vaccine could be a breakthrough in treating the deadly and aggressive type of brain cancer that killed Tom Parker.
The Wanted singer died at the age of just 33 in 2022 after being diagnosed with malignant glioblastoma, a deadly type of tumour that is currently considered incurable.
The jab, which was tested on four adult patients, was found to have trained their immune systems to recognise the cancer cells and fight against them, preventing the tumour from growing unchecked
The vaccine, like other experimental treatments being studied, contains pieces of patients' own tumours - meaning no two shots are the same.
These cancer particles are designed to look like a dangerous virus when reinjected into the bloodstream, prompting the body to attack the remaining tumour in the brain.
The first human trial of the shot, tested on just four patients, found it triggers a strong immune response two days after injection.
It has been developed by researchers from the University of Florida and uses the same mRNA technology pioneered during Covid.
The breakthrough means scientists will now be able to test the vaccine on a larger group of brain cancer patients.
Some 24 people will be recruited to the next part of the trial.
Senior study author Elias Sayour, a University of Florida Health paediatric oncologist, said: 'In less than 48 hours, we could see these tumours shifting from what we refer to as 'cold' – immune cold, very few immune cells, very silenced immune response – to 'hot', very active immune response.
'That was very surprising given how quick this happened, and what that told us is we were able to activate the early part of the immune system very rapidly against these cancers, and that's critical to unlock the later effects of the immune response.'
It gives hopes to people fighting the disease, which has also claimed the lives of Labour politician Tess Jowell, US Senator John McCain and President Joe Biden's son, Beau.
The NHS has said it hopes cancer vaccines will be available to thousands of patients in the UK within the next five years, with experts saying these new types of treatments could offer hopes to people diagnosed with presently untreatable forms of the disease.
Glioblastoma has an average survival of around 15 months, and the current standard of care involves surgery, radiation and some combination of chemotherapy.
Researchers say the discovery represents a potential new way to activate the immune system to fight notoriously treatment-resistant cancers using an iteration of mRNA technology similar to Covid-19 vaccines."
Does the article Insinuate that no cancer vaccines will be available within 5 years, when currently, Northwest Biotherapeutics have filed for MHRA approval of DCVax-L in the UK late december 2023?
The article from the Daily Mail does not insinuate that no cancer vaccines will be available within the next five years. In fact, it suggests optimism about the availability of cancer vaccines, stating that the NHS hopes such vaccines will be accessible to thousands of patients in the UK within the next five years. The focus of this article is on a new type of cancer vaccine for glioblastoma that utilizes mRNA technology, similar to Covid-19 vaccines.
The mention of Northwest Biotherapeutics and their DCVax-L vaccine, which is a different kind of cancer vaccine, does not conflict with the information provided in the Daily Mail article. It appears that various types of cancer vaccines, including the one discussed in the article and DCVax-L, are at different stages of development and approval processes. Therefore, the article supports the idea of emerging cancer vaccine technologies being developed and potentially available in the near future.
